会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明申请
    • METHODS OF ENHANCING IMMUNE RESPONSE IN THE INTRADERMAL COMPARTMENT AND COMPOUNDS USEFUL THEREOF
    • 增强室内免疫反应的方法及其有效的化合物
    • US20090304744A1
    • 2009-12-10
    • US12368864
    • 2009-02-10
    • Robert L. CampbellKevin G. DolanJason B. AlarconJohn A. MiksztaWendy WoodleySheetal Mehta
    • Robert L. CampbellKevin G. DolanJason B. AlarconJohn A. MiksztaWendy WoodleySheetal Mehta
    • A61K39/145A61P37/04
    • A61K39/39A61K31/7048A61K39/12A61K39/145A61K2039/55511A61K2039/55516A61K2039/55555A61K2039/55588C12N2760/16134Y02A50/388Y02A50/466
    • The present invention relates to immunogenic compositions for intradermal delivery of an antigenic or immunogenic agent in combination with one or more excipients. The immunogenic compositions of the invention comprise an antigenic or immunogenic agent and at least one excipient which acts as an adjuvant, i.e., enhances the immune response to the antigenic or immunogenic agent, once delivered to the intradermal compartment of a subject's skin. The immunogenic compositions of the invention comprise an excipient which when administered to the intradermal compartment of skin in accordance with the invention demonstrate adjuvant activity. The immunogenic compositions of the invention have enhanced efficacy as the excipients of the composition cause an asymptomatic skin irritation and recruit antigen presenting cells to the intradermal compartment and thus enhance presentation and/or availability of the antigenic or immunogenic agent to the antigen presenting cells. The enhanced efficacy of the immunogenic compositions of the invention may result in a therapeutically effective immune response after a single intradermal dose, with lower doses of antigenic or immunogenic agent than conventionally used, and without the need for booster immunizations.
    • 本发明涉及用于皮内递送抗原性或免疫原性试剂与一种或多种赋形剂组合的免疫原性组合物。 本发明的免疫原性组合物包含抗原或免疫原性试剂和至少一种充当佐剂的赋形剂,即一旦递送到受试者的皮肤的真皮内隔室,则增强对抗原或免疫原性试剂的免疫应答。 本发明的免疫原性组合物包含赋形剂,其当根据本发明施用于皮肤的皮内隔室时显示佐剂活性。 本发明的免疫原性组合物具有增强的功效,因为组合物的赋形剂引起无症状的皮肤刺激并将抗原呈递细胞募集到皮内区室,从而增强抗原呈递细胞的抗原或免疫原性的呈递和/或可用性。 本发明的免疫原性组合物的增强的功效可以在单次真皮内剂量之后产生治疗有效的免疫应答,具有比常规使用的更低剂量的抗原性或免疫原性试剂,并且不需要加强免疫。
    • 3. 发明授权
    • Molecules enhancing dermal delivery of influenza vaccines
    • 分子增强流感疫苗的皮肤输送
    • US07588774B2
    • 2009-09-15
    • US11006422
    • 2004-12-06
    • Robert L. CampbellKevin G. DolanWendy D. Woodley
    • Robert L. CampbellKevin G. DolanWendy D. Woodley
    • A61K39/00A61K39/39A61K39/12A61K39/02
    • A61K9/0021A61K39/12A61K39/145A61K39/39A61K2039/54A61K2039/55555A61K2039/55583A61K2039/70C12N2760/16134C12N2760/16234Y02A50/386
    • The present invention relates to dermal vaccine formulations, designed for targeted delivery of an immunogenic composition to a dermal compartment of skin including the intradermal and epidermal compartments. The dermal vaccine formulations of the invention comprise an antigenic or immunogenic agent, and at least one molecule, e.g., a chemical agent, which enhances the presentation and/or availability of the antigenic or immunogenic agent to the immune cells of the intradermal compartment or epidermal compartment resulting in an enhanced immune response. The dermal vaccine formulations of the invention have enhanced efficacy as the antigenic or immunogenic agent is delivered to the intradermal compartment or epidermal compartment with enhanced presentation and/or availability to the immune cells that reside therein. The enhanced efficacy of the dermal vaccine formulations results in a therapeutically effective immune response after a single intradermal or epidermal dose, with lower doses of antigenic or immunogenic agent than conventionally used, and without the need for booster immunizations.
    • 本发明涉及真皮疫苗制剂,其设计用于将免疫原性组合物靶向递送至包括皮内和表皮隔层的皮肤皮肤隔室。 本发明的真皮疫苗制剂包含抗原或免疫原性试剂和至少一种分子,例如化学试剂,其增强抗原或免疫原性试剂对皮内隔室或表皮的免疫细胞的呈递和/或可用性 隔室导致增强的免疫应答。 本发明的真皮疫苗制剂具有增强的功效,因为将抗原性或免疫原性药物递送至真皮内室或表皮隔室,其中存在于其中的免疫细胞具有增强的呈递和/或可用性。 真皮疫苗制剂的增强功效在单次真皮内或表皮剂量后产生治疗有效的免疫应答,其具有比常规使用的更低剂量的抗原性或免疫原性剂量,并且不需要加强免疫。